when the 4C is released, the market will head straight to cash receipts and cash on hand.
I'm predicting cash receipts to be between $20k and $80k for the quarter despite them saying for the past 9 months "increasing revenues from life sciences"
and this amount also includes AnteoX.
Pessimistic? No. With this company, if no material news before 4C, you can expect another dismal quarter revenue wise
2022 Dec Quarter 4C:
"Growth opportunities being pursued through AnteoTech’s AnteoBind product are expected to deliver
growing revenue streams in the short-term."
ADO Charting and Technical Analysis, page-7927
-
- There are more pages in this discussion • 1,312 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(2.38%) |
Mkt cap ! $51.83M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $37.27K | 1.848M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 914181 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 588561 | 1 |
View Market Depth
| Last trade - 13.23pm 24/06/2024 (20 minute delay) ? |
| ADO (ASX) Chart |